UIC-2019-166 – Anti-Human Saposin C Mouse Monoclonal Antibody

UIC researcher, Dr. Craig Beattie, created a murine IgG1 monoclonal antibody against Saposin C with purified human Saposin C as the initial immunogen. The antibody, termed 68-12, maps within Saposin C and within that region of its precursor Prosaposin. This enables targeting of both Saposin C and the Saposin C region of Prosaposin. The antibody […]

UIC-2019-079 – Novel, Bifunctional Chelating Agent

Leading chemistry research labs at UIC, the Wardrop and Miller labs, present a novel 4-C functionalized- 1,2-trans-cyclohexyldiamine chelating agent. The primary embodiment would be 4-C functionalized CyDTPA, meaning the conjugation site is distal to the coordination sphere. 4-C functionalization minimizes interactions between the conjugate and the coordination sphere. Moreover, the synthetic pathway yields a single […]

UIC-2018-071 – Anti-Kinesin Light Chain (KLC) Mouse Monoclonal Antibody

UIC researchers, Scott Brady and Gerardo Morfini, created anti-KLC (63-90) with purified rat brain KLC1 as the initial immunogen1. The antibody maps within the N-terminal region. The 63-90 antibody has no effect on the axonal transport or membrane association of kinesin. The antibody also does not affect the ability of kinesin to bind microtubules or […]

UIC-2018-001 – Novel, First-in-class therapeutic strategy for asthma treatment

300 million people worldwide suffer from asthma, with 60 million cases in the United States. There are a staggering 180,000 annual asthma-related deaths worldwide. The annual direct cost of asthma treatment is approximately 50 billion USD, and the asthma prescription drug market was 30 billion USD in 2016. The economic impact of asthma are estimated […]

UIC-2012-013 – Pharmaceutical Compositions for Sleep Disorders

UIC researchers propose pharmacologic compositions with demonstrated efficacy in two human pilot studies. Exemplary embodiments consist of a combination regimen of ondansetron (24 mg/day) and fluoxetine (10 mg/day). Both clinical studies evidence a significant improvement of patient apnea–hypopnea index (AHI) over baseline severity. Neither studies observed a significant difference in adverse events from drug treatment. […]